Implementing fragmentomics into real world screening interventions to evaluate clinical utility among individuals with elevated risk for lung cancer (FIRSTLUNG) L301. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results